Group 1 - The stock price of You Ning Wei is 34.05 yuan, down 0.21 yuan from the previous trading day, with a trading range of 33.73 yuan to 34.55 yuan and a trading volume of 15,874 hands, amounting to 54 million yuan [1] - You Ning Wei operates in the biopharmaceutical industry, focusing on the research, production, and sales of life science reagents and related products, with headquarters in Shanghai [1] - As of August 4, You Ning Wei was surveyed by one fund company, and among the six companies surveyed that day, its total market capitalization was less than 10 billion yuan [1] Group 2 - On August 5, the net outflow of main funds from You Ning Wei was 2.0785 million yuan, accounting for 0.11% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow reached 3.3885 million yuan, representing 0.18% of the circulating market value [1]

市场表现上，基金调研股中，近5日上涨的有5只，涨幅居前的有威尔高、优宁维、科士达等，涨幅为 5.59%、2.10%、1.54%；下跌的有1只，跌幅居前的有中旗新材等，跌幅为4.35%。 业绩方面，基金调研公司中，公布上半年业绩预告的共有2家，业绩预告类型来看，预增有1只。以净利 润增幅中值来看，净利润增幅最高的是威尔高，预计净利润中值为4650.00万元，同比增幅为21.71%。 （数据宝） 8月4日基金调研公司一览 昨日基金共对6家公司进行调研，扎堆调研东威科技、泰恩康等。 证券时报·数据宝统计，8月4日共8家公司被机构调研，按调研机构类型看，基金参与6家公司的调研活 动。东威科技最受关注，参与调研的基金达59家；泰恩康、威尔高等分别获38家、3家基金集体调研。 基金参与调研的公司中，按所属板块统计，深市主板公司有2家，创业板公司有3家，科创板公司有1 家。 从基金调研公司的A股总市值统计，总市值不足100亿元的有3家，分别是优宁维、威尔高、中旗新材 等。 | 代码 | 简称 | 基金家数 | 最新收盘价（元） | 近5日涨跌幅（%） | 行业 | | --- | --- | --- | --- | --- ...

Group 1: Research Basic Information - The research object is Youningwei, belonging to the professional services industry, with a reception time of August 4, 2025. The listed company's reception staff includes Deputy General Manager and Board Secretary Qi Yanfang, and Securities Affairs Representative Xia Qingli [17] Group 2: Detailed Research Institutions - The reception objects include Huitong Fund (a fund management company) and Tianling Investment (an investment company) [18] Group 3: Main Content Information - The company is a one - stop service provider in life sciences, offering products and services such as reagents, consumables, instruments, and laboratory services. It currently has a product structure with agency products as the main part and self - owned brand products as a supplement. In 2024, the total revenue of self - owned brand products increased by nearly 30% year - on - year [22] - The overall gross margin of the company's self - owned brand is about 50%, and the revenue is expected to increase in proportion as the company invests more in sales resources and enriches product pipelines [22] - In 2024, the company launched a share repurchase plan, using 25,987,076 yuan of its own funds to repurchase 927,600 shares for equity incentives or employee stock ownership plans, and will launch relevant plans according to business development [22] - The company's business is mainly in the domestic market. It will accelerate the overseas expansion of self - owned brand products based on R & D and domestic sales, and established a company in Singapore in 2024. It also promotes products through online and offline means [22][23] - The company will strengthen channel and R & D capabilities around the "Two Extremes Strategy". In terms of external expansion, it will seek investment and cooperation with potential upstream and downstream target enterprises with synergistic effects, mainly product - type companies related to antibody applications [23]

Group 1: Company Product Structure - The company operates as a one-stop service provider in life sciences, offering reagents, consumables, instruments, and laboratory services, integrating both well-known domestic and international brands as well as its own brands [1] - In 2024, the revenue from the company's own brands increased by nearly 30% year-on-year, indicating a strong growth trend [1] Group 2: Own Brand Performance - The overall gross margin for the company's own brands is approximately 50% [1] - The revenue share from own brands is currently low, but it is expected to increase as the company invests more resources into sales and continues to enrich its product pipeline [1] Group 3: Shareholder Incentives - In 2024, the company initiated a share repurchase plan, utilizing a total of 25,987,076 CNY to repurchase 927,600 shares, which will be used for equity incentives or employee stock ownership plans [1] - Future equity incentive or employee stock ownership plans will be introduced based on business development needs [1] Group 4: Overseas Market Expansion - The company's business is primarily focused on the domestic market, but it plans to accelerate the internationalization of its own brand products based on R&D and domestic sales performance [2] - In 2024, the company established a subsidiary in Singapore to facilitate overseas expansion [2] - The company is actively enhancing product visibility through online promotions and participation in offline exhibitions to further accelerate overseas market development [2] Group 5: M&A Strategy - The company aims to strengthen channel capabilities and R&D capabilities to better serve customers and provide a diverse range of products and services [2] - In terms of external growth, the company will seek potential upstream and downstream acquisition targets that align with its existing business, particularly in antibody-related applications [2]

优宁维（301166.SZ）8月4日在投资者互动平台表示，投资者您好，公司参与投资的股权投资基金主要 投向医疗健康、数字经济、先进制造等领域。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：介绍下贵公司的创投投资了哪几个主要企业，他们前 景如何？ ...

Core Viewpoint - The company has approved the use of idle raised funds and self-owned funds for cash management, with a total limit of RMB 180 million, ensuring that it does not affect project construction or normal operations [1] Group 1: Cash Management Approval - The company and its subsidiaries are authorized to use up to RMB 30 million of idle raised funds and RMB 150 million of self-owned funds for cash management, effective for 12 months starting from March 9, 2025 [1] - Independent directors and the sponsor institution have expressed their agreement with the cash management proposal [1] Group 2: Investment Risk Analysis - The company plans to invest in structured deposit products, which are considered low-risk, but acknowledges potential market volatility affecting returns [2] - Risk control measures include timely analysis of cash management products and maintaining close contact with financial institutions to monitor fund operations [2][3] Group 3: Impact on Daily Operations - The use of idle self-owned funds for cash management is based on principles of risk prevention and prudent investment, ensuring the safety of the principal [5] - This approach is expected to enhance fund utilization efficiency and generate investment returns, ultimately benefiting the company and its shareholders [5] Group 4: Previous Cash Management Activities - As of August 1, 2025, the company has an outstanding balance of RMB 70 million in raised funds and RMB 920 million in self-owned funds invested in structured deposit products [6]

Core Viewpoint - The company has approved a share repurchase plan, intending to buy back shares using its own funds within a specified price range and timeframe [1][2]. Summary by Sections Share Repurchase Plan - The company plans to repurchase shares with a budget between RMB 15 million and RMB 30 million, with a maximum repurchase price set at RMB 44 per share [1]. - Following the annual equity distribution on May 22, 2025, the maximum repurchase price was adjusted to RMB 43.77 per share [2]. Progress of Share Repurchase - As of July 31, 2025, the company has not yet repurchased any shares, with the total repurchased shares standing at 0, which is 0% of the total share capital [2]. Compliance and Regulations - The share repurchase plan complies with relevant laws, regulations, and the company's own guidelines [3][4]. - The company has not engaged in share repurchase during periods that could significantly impact the trading price of its securities [4]. - The repurchase will be conducted through centralized bidding, adhering to specific trading restrictions [5]. Future Actions - The company will continue to implement the repurchase plan based on market conditions and will fulfill its information disclosure obligations as required by law [5].

Group 1 - The company, Youningwei, announced on August 1 that as of July 31, 2025, it has not repurchased any shares through its dedicated securities account, representing 0% of the total share capital [2] - The company has not yet implemented the planned share repurchase [2]

证券代码：301166 证券简称：优宁维 公告编号：2025-062 上海优宁维生物科技股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 上海优宁维生物科技股份有限公司（以下简称"公司"或"优宁维"）于 2025 年 2 月 17 日召开第四届董事会第三次会议和第四届监事会第三次会议，2025 年 3 月 7 日召开 2025 年第二次临时股东大会，审议通过了《关于使用闲置募集资 金及自有资金进行现金管理的议案》，同意公司及并表范围内的子孙公司在不影 响募集资金投资项目建设、不影响公司正常生产经营及确保资金安全的情况下， 使用不超过人民币 30,000 万元（含本数）的闲置募集资金及不超过人民币 150,000 万元（含本数）的自有资金进行现金管理，使用期限自 2025 年 3 月 9 日起 12 个 月内有效。公司独立董事和保荐机构均发表了同意意见。具体内容详见公司分别 于 2025 年 2 月 19 日和 2025 年 3 月 8 日刊载于巨潮资讯网（www.cninfo.com.cn） 的相关公告。 ...

公司 2024 年度权益分派于 2025 年 5 月 22 日实施完毕，根据《关于回购公 司股份方案的公告》《回购报告书》，公司本次以集中竞价交易方式回购股份价 格上限由不超过人民币 44 元/股调整为不超过人民币 43.77 元/股，回购价格调整 起始日为 2025 年 5 月 22 日（除权除息日）。具体内容详见公司于 2025 年 5 月 22 日披露于巨潮资讯网的《关于 2024 年度权益分派实施后调整回购股份价格上 限的公告》。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号—回购股份》等相关规定，上市公司应当在每个月的前三个交易日内，披露 截至上月末的回购进展情况。现将公司回购股份的进展情况公告如下： 一、回购公司股份的进展情况 截至 2025 年 7 月 31 日，公司通过股份回购专用证券账户以集中竞价交易方 式累计回购公司股份 0 股，占公司总股本的 0%，公司暂未实施本次股份回购。 证券代码：301166 证券简称：优宁维 公告编号：2025-061 上海优宁维生物科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 ...